Brief: Eagle Pharmaceuticals Announces First Patient Randomized In Phase 2 Study Evaluating CAL02 In Severe Community-Acquired Bacterial Pneumonia
24/07/2023 12:41
July 24 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS ANNOUNCES FIRST PATIENT RANDOMIZED
IN
PHASE 2 STUDY EVALUATING CAL02, A NOVEL FIRST-IN-CLASS
ANTI-TOXIN DRUG CANDIDATE, IN SEVERE COMMUNITY-ACQUIRED
BACTERIAL PNEUMONIA (SCABP)
* EAGLE PHARMACEUTICALS -BELIEVES CAL02 IS A NCE WHICH WOULD
RESULT IN 5 YEARS OF MARKETING EXCLUSIVITY UPON APPROVAL OR 3
YEARS WITHOUT NCE DESIGNATION
* EAGLE PHARMACEUTICALS INC - DEPENDING UPON RECRUITMENT
RATES,
EAGLE ANTICIPATES HAVING ITS FIRST 50% INTERIM REPORT AROUND Q1
OF 2024
Source text for Eikon: ID:nGNX2wgBHm
Further company coverage: EGRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq